| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | CD40 ligand |
| Clinical data | |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| PubChem SID | |
| ChemSpider |
|
| KEGG |
|
Frexalimab (SAR441344) is a second-generation monoclonal antibody that inhibits CD40 ligand. It is in development by Sanofi for the treatment of relapsing multiple sclerosis.
Demyelinating diseases of the central nervous system | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Signs and symptoms | |||||||||
| Investigations and diagnosis |
| ||||||||
| Approved treatment | |||||||||
| Other treatments | |||||||||
| Demyelinating diseases |
| ||||||||
| Other | |||||||||
Monoclonal antibodies for the immune system | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Immune system |
| ||||||||||
| Interleukin |
| ||||||||||
| Inflammatory lesions |
| ||||||||||
| |||||||||||